

Financial Tear Sheet

Corporate Profile

We are a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. We have a comprehensive portfolio of orthobiologics and spinal implants solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. Our orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. Our spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in minimally invasive surgery (MIS), complex spine, deformity and degenerative procedures. Expertise in both orthobiologic sciences and spinal implants product development allow us to offer our surgeon customers a differentiated portfolio and a complete procedural solution to meet their fusion requirements. We currently markets our products in the United States and in over 30 countries worldwide.

Stock Performance

SPNE (Common Stock)

| | |
|--------------------|--------------------|
| Exchange | NASDAQ (US Dollar) |
| Price | \$17.90 |
| Change (%) | ▼ 0.01 (0.06%) |
| Volume | 88,807 |
| 52 Week Low | \$9.51 |
| Market Cap | \$331,736,386 |
| Rolling EPS | -4.15 |
| PE Ratio | 0 |
| Shares Outstanding | 18,532,759 |



Data as of 02/22/19 4:00 p.m. ET

Recent News & Upcoming Events

02/19/19

SeaSpine Appoints Kim Commins-Tzoumakas and Renee Gaeta to its Board of Directors

02/14/19

SeaSpine to Report Fourth Quarter and Full Year 2018 Financial Results on February 27, 2019

01/07/19

SeaSpine Announces Preliminary Results for Fourth Quarter and Full-Year 2018

Date

Title

02/27/19 4:30 p.m. ET

Q4 2018 Seaspine Holdings Corp Earnings Conference Call

SEC Filings

| Filing Date | Form |
|-------------|------|
| 02/20/19 | 4 |
| 02/20/19 | 4 |
| 02/20/19 | 3 |
| 02/20/19 | 3 |

Corporate Governance

Keith C. Valentine President, Chief Executive Officer and Director

John J. Bostjancic Senior Vice President, Chief Financial Officer

Dennis Cirino Senior Vice President, Global Spinal Systems

Tyler Lipschultz Senior Vice President, Orthobiologics and Business Development

Laetitia Cousin Vice President, Regulatory and Quality Assurance

Patrick Keran General Counsel and Corporate Secretary

Bill Rhoda General Manager of Process Innovation and Development

| | |
|---------------|---|
| Chris Shen | Vice President, Customer Experience and Information Technology |
| Frank Vizesi | Vice President, Orthobiologics Research & Development, and Clinical Affairs |
| John J. Winge | Vice President, Sales |
| Troy Woolley | Vice President, Marketing |

Data provided by Nasdaq. Minimum 15 minutes delayed.